Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Dec;95(12):1931-1942.
doi: 10.1007/s00277-016-2810-z. Epub 2016 Oct 3.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Richard F Schlenk  1   2 , Michael Lübbert  3 , Axel Benner  4 , Alexander Lamparter  5 , Jürgen Krauter  6   7 , Wolfgang Herr  8   9 , Hans Martin  10 , Helmut R Salih  11 , Andrea Kündgen  12 , Heinz-A Horst  13 , Peter Brossart  14 , Katharina Götze  15 , David Nachbaur  16 , Mohammed Wattad  17 , Claus-Henning Köhne  18 , Walter Fiedler  19 , Martin Bentz  20 , Gerald Wulf  21 , Gerhard Held  22 , Bernd Hertenstein  23 , Hans Salwender  24 , Verena I Gaidzik  5 , Brigitte Schlegelberger  25 , Daniela Weber  5 , Konstanze Döhner  5 , Arnold Ganser  24 , Hartmut Döhner  5 ; German-Austrian Acute Myeloid Leukemia Study Group
Affiliations
Randomized Controlled Trial

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Richard F Schlenk et al. Ann Hematol. 2016 Dec.

Abstract

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18-60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6-8; 15 mg/m2, days 9-21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred patients were randomized (556, STANDARD; 544, ATRA) with 38 patients treated vice versa. Median follow-up for survival was 5.2 years. ITT analyses revealed no difference between ATRA and STANDARD for the total cohort and for the subset of NPM1-mutated AML with respect to event-free (EFS; p = 0.93, p = 0.17) and overall survival (OS; p = 0.24 and p = 0.32, respectively). Pre-specified PP analyses revealed better EFS in NPM1-mutated AML (p = 0.05) and better OS in the total cohort (p = 0.03). Explorative subgroup analyses on an ITT basis revealed better OS (p = 0.05) in ATRA for genetic low-risk patients according to ELN recommendations. The clinical trial is registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95).

Keywords: Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards Conflicts of interest Authors indicated no potential conflict of interest. Authors’ contribution Conception and Design: Richard F. Schlenk, Michael Lübbert, Hartmut Döhner Provision of study materials or patients: Richard F. Schlenk, Michael Lübbert, Jürgen Krauter, Thomas Kindler, Hans Martin, Helmut R. Salih, Andrea Kündgen, Heinz-A. Horst, Peter Brossart, Katharina Götze, David Nachbaur, Mohammed Wattad, Claus-Henning Köhne, Walter Fiedler, Martin Bentz, Gerald Wulf, Gerhard Held, Bernd Hertenstein, Hans Salwender, Verena I Gaidzik, Brigitte Schlegelberger, Konstanze Döhner, Arnold Ganser, Hartmut Döhner. Collection and assembly of data: Richard F. Schlenk, Alexander Lamparter, Daniela Weber. Data analysis and interpretation: Richard F. Schlenk, Alexander Lamparter, Axel Benner, Hartmut Döhner. Manuscript writing: Richard F. Schlenk, Hartmut Döhner. Final approval of manuscript: Richard F. Schlenk, Michael Lübbert, Axel Benner, Alexander Lamparter, Jürgen Krauter, Thomas Kindler, Hans Martin, Helmut R. Salih, Andrea Kündgen, Heinz-A. Horst, Peter Brossart, Katharina Götze, David Nachbaur, Mohammed Wattad, Claus-Henning Köhne, Walter Fiedler, Martin Bentz, Gerald Wulf, Gerhard Held, Bernd Hertenstein, Hans Salwender, Verena I Gaidzik, Brigitte Schlegelberger, Daniela Weber, Konstanze Döhner, Arnold Ganser, Hartmut Döhner.

Figures

Fig. 1
Fig. 1
Flow chart on study conduct. Flow chart showing enrollment, program completion and/or drop-out according to the randomization result. Abbreviations: IC informed consent, RD refractory disease, HCT hematopoietic cell transplantation
Fig. 2
Fig. 2
Survival analyses according to randomization according to intention-to-treat and per-protocol analysis
Fig. 3
Fig. 3
Survival after relapse according to European LeukemiaNet (ELN) classification analyzed on an intention-to-treat basis. a ELN favorable-risk group; b all other ELN risk groups
See this image and copyright information in PMC

References

    1. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21. doi: 10.1056/NEJMoa1300874. - DOI - PubMed
    1. Lo-Coco F, Di Donato L, GIMEMA. Schlenk RF, German–Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med. 2016;374(12):1197–8. doi: 10.1056/NEJMc1513710. - DOI - PubMed
    1. Hu ZB, Minden MD, McCulloch EA. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia. 1995;9:1667–73. - PubMed
    1. Yang GS, Minden MD, McCulloch EA. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia. 1993;7:1012–9. - PubMed
    1. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881–92. doi: 10.1038/sj.leu.2401573. - DOI - PubMed

Publication types